Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: London : Nature Publishing Group, copyright 2011-
    • الموضوع:
      Prognosis*; Brain Neoplasms/*genetics ; Breast Neoplasms/*genetics ; Receptor, ErbB-2/*genetics; Ado-Trastuzumab Emtansine/administration & dosage ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Brain Neoplasms/drug therapy ; Brain Neoplasms/epidemiology ; Brain Neoplasms/pathology ; Breast Neoplasms/drug therapy ; Breast Neoplasms/epidemiology ; Breast Neoplasms/pathology ; Disease-Free Survival ; Female ; Humans ; Middle Aged ; Neoplasm Metastasis ; Receptors, Progesterone/genetics
    • نبذة مختصرة :
      In metastatic breast cancer (mBC), the change of human epidermal growth factor receptor 2 (HER2) status between primary and metastatic lesions is widely recognized, however clinical implications are unknown. Our study address the question if relevant differences exist between subjects who preserve the HER2 status and those who gain the HER2 positivity when relapsed. Data of patients affected by HER2-positive mBC, treated with pertuzumab and/or trastuzumab-emtansine (T-DM1) in a real-world setting at 45 Italian cancer centers were retrospectively collected and analyzed. From 2003 to 2017, 491 HER2-positive mBC patients were included. Of these, 102 (20.7%) had been initially diagnosed as HER2-negative early BC. Estrogen and/or progesterone receptor were more expressed in patients with HER2-discordance compared to patients with HER2-concordant status (p < 0.0001 and p = 0.006, respectively). HER2-discordant tumors were characterized also by a lower rate of brain metastases (p = 0.01) and a longer disease free interval (p < 0.0001). Median overall survival was longer, although not statistically significant, in the subgroup of patients with HER2-discordant cancer with respect to patients with HER2-concordant status (140 vs 78 months, p = 0.07). Our findings suggest that patients with HER2-positive mBC with discordant HER2 status in early BC may have different clinical, biological and prognostic behavior compared to HER2-concordant patients.
    • References:
      Appl Immunohistochem Mol Morphol. 2003 Sep;11(3):214-21. (PMID: 12966347)
      Cancer. 2005 May 1;103(9):1763-9. (PMID: 15786420)
      J Clin Oncol. 2012 Jul 20;30(21):2601-8. (PMID: 22711854)
      Crit Rev Oncol Hematol. 2012 Dec;84(3):301-13. (PMID: 22710198)
      J Clin Oncol. 2013 Nov 1;31(31):3997-4013. (PMID: 24101045)
      Lancet. 2011 Nov 19;378(9805):1812-23. (PMID: 22098854)
      Breast Cancer Res Treat. 2016 Dec;160(3):411-424. (PMID: 27761678)
      Eur J Cancer. 2014 Jan;50(2):277-89. (PMID: 24269135)
      Br J Cancer. 2013 Feb 19;108(3):479-85. (PMID: 23299535)
      Eur J Cancer. 2014 Mar;50(5):885-91. (PMID: 24491395)
      Br J Cancer. 2005 Sep 5;93(5):552-6. (PMID: 16106267)
      J Clin Oncol. 2007 Nov 20;25(33):5287-312. (PMID: 17954709)
      Cancer. 1983 Aug 1;52(3):479-85. (PMID: 6861087)
      Onco Targets Ther. 2020 Jan 28;13:853-863. (PMID: 32099389)
      BMC Cancer. 2016 Jul 25;16:522. (PMID: 27456970)
      J Natl Cancer Inst. 2018 Jun 1;110(6):568-580. (PMID: 29315431)
      J Transl Med. 2015 Apr 21;13:126. (PMID: 25896421)
      Cancer Metastasis Rev. 2016 Sep;35(3):427-37. (PMID: 27405651)
      Pathol Oncol Res. 2006;12(3):149-52. (PMID: 16998594)
      Jpn J Clin Oncol. 2011 May;41(5):593-9. (PMID: 21406492)
      Anticancer Res. 2009 May;29(5):1557-62. (PMID: 19443366)
      J Clin Oncol. 2012 Feb 20;30(6):593-9. (PMID: 22124109)
      Eur J Cancer. 2014 Nov;50(17):2916-24. (PMID: 25241230)
      Breast Cancer Res Treat. 2009 Jan;113(2):301-6. (PMID: 18273700)
      J Oncol Pract. 2018 Jul;14(7):437-441. (PMID: 29920138)
      Clin Breast Cancer. 2012 Oct;12(5):340-6. (PMID: 23040002)
      Ann Oncol. 2002 Jul;13(7):1036-43. (PMID: 12176781)
      J Clin Oncol. 2015 Aug 20;33(24):2695-704. (PMID: 26195705)
      Lancet Oncol. 2009 Oct;10(10):933-5. (PMID: 19796747)
    • الرقم المعرف:
      0 (Receptors, Progesterone)
      EC 2.7.10.1 (ERBB2 protein, human)
      EC 2.7.10.1 (Receptor, ErbB-2)
      SE2KH7T06F (Ado-Trastuzumab Emtansine)
    • الموضوع:
      Date Created: 20210703 Date Completed: 20211102 Latest Revision: 20211102
    • الموضوع:
      20231215
    • الرقم المعرف:
      PMC8253801
    • الرقم المعرف:
      10.1038/s41598-021-92774-z
    • الرقم المعرف:
      34215766